Novartis Renin Inhibitor Rasilez Approved In China For Hypertension
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novartis has received regulatory approval in China for Rasilez (aliskiren) for treatment of high blood pressure alone or as a combination therapy with other anti-hypertension drugs, the Swiss company announced July 20. Aliskiren is marketed as Tekturna in the U.S